Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 21, Issue 11, Pages 1661-1678Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.2012.714771
Keywords
agomelatine; antioxidant; blood pressure; circadin; hypertension; melatonin receptor; metabolic syndrome; piromelatine; ramelteon; tasimelteon; TIK-301
Categories
Funding
- Scientific Grant Agency of the Ministry of Education of the Slovak Republic [VEGA 1/0831/11, 1/0227/12, 2/0190/11]
- Agency for Science and Research Support of the Slovak Republic [APVV-0205-11]
Ask authors/readers for more resources
Introduction: Melatonin synchronizes circadian rhythms with light/dark period and it was demonstrated to correct chronodisruption. Several melatonin receptor agonists with improved pharmacokinetics or increased receptor affinity are being developed, three of them are already in clinical use. However, the actions of melatonin extend beyond chronobiology to cardiovascular and metabolic systems as well. Given the high prevalence of cardiovascular disease and their common occurrence with chronodisruption, it is of utmost importance to classify the cardiometabolic effects of the newly approved and putative melatoninergic drugs. Areas covered: In the present review, the available (although very sparse) data on such effects, in particular by the approved (circadin, ramelteon, agomelatine) or clinically advanced (tasimelteon, piromelatine = Neu-P11, TIK-301) compounds are summarized. The authors have searched for an association with blood pressure, vascular reactivity, ischemia, myocardial and vascular remodeling and metabolic syndrome. Expert opinion: The data suggest that cardiovascular effects of melatonin are at least partly mediated via MT1/MT2 receptors and associated with its chronobiotic action. Therefore, despite the sparse direct evidence, it is believed that these effects will be shared by melatonin analogs as well. With the expected approval of novel melatoninergic compounds, it is suggested that the investigation of their cardiovascular effects should no longer be neglected.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available